Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database
| العنوان: | Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database |
|---|---|
| المؤلفون: | Sebastian Haferkamp, Florian Scholz, Hartmut Richter, Victoria Banks, Peter Mohr, Katarina Öhrling, Karly S. Louie |
| المصدر: | Future Oncology. 16:317-328 |
| بيانات النشر: | Future Medicine Ltd, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Volume Administered, Databases, Factual, Patient characteristics, Herpesvirus 1, Human, Kaplan-Meier Estimate, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Prescription database, Germany, Internal medicine, medicine, Humans, Summary of Product Characteristics, Medical prescription, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Oncolytic Virotherapy, Biological Products, business.industry, Retrospective cohort study, General Medicine, Guideline, Middle Aged, Prognosis, Combined Modality Therapy, Oncolytic Viruses, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Talimogene laherparepvec, business, Follow-Up Studies |
| الوصف: | Aim: There is a growing body of data on real-world use of talimogene laherparepvec (T-VEC). We aimed to characterize real-world T-VEC use using a nationally representative German prescription database covering 60% of prescriptions reimbursed. Patients & methods: A retrospective analysis was conducted using the German IMS® LRx prescription database, analyzing patients aged ≥18 years with an initial T-VEC prescription at 106 plaque-forming units (PFU)/ml and ≥1 subsequent prescription at 108 PFU/ml. Median time on T-VEC treatment, patient characteristics and patterns of T-VEC use were described. Results: Of 127 patients prescribed T-VEC, 72 patients (57%) met study criteria. About two-thirds of these patients initiated T-VEC in 2017. Median age at T-VEC initiation was 74 years (range: 44 to 91). Most prescriptions (88%) were dispensed from hospitals. At study end, 26 (36%) patients remained on T-VEC; 46 (64%) had ended treatment. Median duration of T-VEC treatment for all patients was 18.7 weeks (95% CI: 15.3–26.9) and was longer among those who initiated treatment in 2017 versus 2016 (26.7 vs 15.6 weeks, respectively). Median volume administered for the first 106 PFU/ml and second 108 PFU/ml was 4 ml; the volume decreased for subsequent administrations (2 ml by the eighth administration and 1 ml by the 16th administration). Conclusion: This real-world prescription database study showed that patients who initiated treatment in 2017 had a treatment duration in clinical practice that corresponded with the European Summary of Product Characteristics guideline of continuing T-VEC for ≥6 months. Additional long-term data linking drug use with clinical outcomes are needed. |
| تدمد: | 1744-8301 1479-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95bbaa7aa6794049cfd27431febefc9Test https://doi.org/10.2217/fon-2019-0838Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c95bbaa7aa6794049cfd27431febefc9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448301 14796694 |
|---|